Immunotherapy and liver transplantation: A narrative review of basic and clinical data
CH Wassmer, S El Hajji, X Papazarkadas… - Cancers, 2023 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) represents one of the main indications
for liver transplantation. Over recent years, immune checkpoint inhibitor (ICI) therapy has …
for liver transplantation. Over recent years, immune checkpoint inhibitor (ICI) therapy has …
Safety and efficacy of atezolizumab and bevacizumab combination as a first line treatment of advanced hepatocellular carcinoma
V Zanuso, A Pirozzi, R Balsano… - Journal of …, 2023 - Taylor & Francis
Hepatocellular carcinoma (HCC) is one of the most common leading causes of cancer death
worldwide. As most patients are diagnosed with advanced disease, systemic therapy …
worldwide. As most patients are diagnosed with advanced disease, systemic therapy …
Clinical outcomes associated with monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for advanced hepatocellular …
Simple Summary Hepatocellular carcinoma (HCC) is one of the most malignant tumors.
Immune checkpoint inhibitors (ICIs)-based therapy has recently been demonstrated to …
Immune checkpoint inhibitors (ICIs)-based therapy has recently been demonstrated to …
[HTML][HTML] Combined hepatocellular cholangiocarcinoma: A clinicopathological update
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer
associated with an appalling prognosis. The diagnosis and management of this entity have …
associated with an appalling prognosis. The diagnosis and management of this entity have …
Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors
Background Programmed cell death protein-1 (PD-1) inhibitors have shown promising
clinical efficacy in treating advanced hepatocellular carcinoma (HCC). However, little …
clinical efficacy in treating advanced hepatocellular carcinoma (HCC). However, little …
Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis
S Li, Z Zhang, Z Wang, K Wang, M Sui… - Oncology …, 2024 - spandidos-publications.com
Hepatocellular carcinoma (HCC) is a malignancy associated with high morbidity and
mortality rates. Conversion therapy provides patients with unresectable HCC (uHCC) the …
mortality rates. Conversion therapy provides patients with unresectable HCC (uHCC) the …
Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular …
Y Sheng, Q Wang, HF Liu, Q Wang… - British Journal of …, 2024 - academic.oup.com
Objectives To establish and verify a prognostic nomogram model for selecting in
unresectable hepatocellular carcinoma (uHCC) treated by transarterial chemoembolization …
unresectable hepatocellular carcinoma (uHCC) treated by transarterial chemoembolization …
Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma
Renal cell carcinoma originates from the lining of the proximal convoluted renal tubule and
represents the most common type of kidney cancer. Risk factors and comorbidities might be …
represents the most common type of kidney cancer. Risk factors and comorbidities might be …
[PDF][PDF] Comparing the clinical efficacy and safety of second-line targeted therapy and immunotherapy in patients with mid-to advanced stages of hepatocellular …
JF Li, YX Fu, HC Zhang, H Ma… - European Review for …, 2023 - europeanreview.org
OBJECTIVE: The aim of this study was to examine the efficacy and safety of second-line
immunotherapy and targeted treatment in hepatocellular carcinoma (HCC). MATERIALS …
immunotherapy and targeted treatment in hepatocellular carcinoma (HCC). MATERIALS …
Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma
Background The objective of this study was to systematically analyse methodological and
structural assumptions utilised in model-based health economic evaluations of systemic …
structural assumptions utilised in model-based health economic evaluations of systemic …